Lilly's Alimta approved as maintenance therapy in advanced NS NSCLC
This article was originally published in Scrip
Executive Summary
The US FDA has given the go-ahead for Lilly's Alimta (pemetrexed for injection) to be used in a continuation maintenance setting for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NS NSCLC) – an expanded indication.